Interferon alpha in the therapy of conjunctival lymphoma in an HIV+ patient.
The authors evaluated the efficacy of interferon-alpha used intralesionally in the therapy of low-grade conjunctival non-Hodgkin lymphoma in an HIV-positive patient. The patient received one intralesional injection of 1,000,000 U of interferon-alpha three times a week for a total of twelve doses. The remission of conjunctival involvement was seen three months from the end of therapy. The intralesional use of interferon-alpha can be considered an efficacious therapy for low-grade conjunctival non-Hodgkin lymphoma.
Cellini
M
M
Institute of Ophthalmology, University of Bologna, Italy.
Possati
G L
GL
Puddu
P
P
Caramazza
R
R
D003230:Conjunctival Neoplasms / Q000473:pathology / Q000628:therapy*; D005260:Female; D006679:HIV Seropositivity / Q000150:complications*; D006801:Humans; D015552:Injections, Intralesional; D016898:Interferon-alpha / Q000627:therapeutic use*; D018442:Lymphoma, B-Cell, Marginal Zone / Q000473:pathology / Q000628:therapy*; D008875:Middle Aged; D012074:Remission Induction
D016898:Interferon-alpha